Filed with ASX · · 15 pages · English
Neurizon Therapeutics Limited has issued a reminder for an upcoming investor webinar featuring its CEO and CFO, scheduled for November. The presentation will cover the company's recent capital raise and funding strategy ahead of the HEALEY trial results expected in the future. Neurizon is focused on developing therapies for neurodegenerative diseases, with its lead drug candidate currently in clinical trials. The company aims to strengthen its funding position and provide updates on its clinical development priorities during the webinar.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Investor webinar reminder and presentation Highlights: ? Shareholders and interested investors are invited to join Neurizon’s investor webinar featuring CEO Dr Chris Bremer and CFO Mr Dan O’Connell ? Investor webinar to be held...
Neurizon Therapeutics Limited on 6ix
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics